leadf
logo-loader
RNS
view4D pharma plc

4d Pharma PLC - 4D hosts virtual R&D event

RNS Number : 7284X
4d Pharma PLC
01 September 2020
 

 

4D pharma plc

 

(the "Company" or "4D")

 

4D pharma hosts R&D webinar providing an overview of world leading Live Biotherapeutic discovery platform, MicroRx®

 

 

Leeds, UK, 1 September, 2020 - 4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutics, has today made available its recorded R&D webinar discussing the science behind their Live Biotherapeutic drug discovery engine, MicroRx®.

 

 

The event is introduced by Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma, and presented by Dr Imke Mulder, Research Director, 4D pharma, alongside three senior members of her Research team. The presentation provides detailed insights in to 4D's MicroRx platform, followed by covering analysts participating in a question and answer session.

 

Topics include:

·    Why 4D's focus on the mechanism of single-strain LBPs drives a rational drug discovery approach and guides effective development

·    How the MicroRx platform investigates functionality

·    The drug discovery process and considerations for the microbiome

·    4D's proprietary culture collection

·    Neurodegenerative diseases and 4D pharma candidates - MRx0029 and MRx0005

·    MRx0518, oncology and the MicroRx platform

 

 

The presentation slides and recording of the event are accessible via the "Reports and Presentations" area of 4D's website at www.4dpharmaplc.com/en/investors/reports-presentations.

 

The microbiome is a novel area of medicine with profound impacts on human health and disease.  4D pharma recently announced proof of concept data for their lead immuno-oncology candidate MRx0518 in combination with Keytruda, highlighting that the 42% disease control rate observed in Part A of the study, far exceeded the predefined 10% threshold for expansion. This, in addition with 4D pharma holding the largest IP portfolio and working in diverse therapy areas, has driven increased interest in the Company's science and development from a range of stakeholders.

 

Dr Imke Mulder has led the multidisciplinary research group at 4D pharma since 2014, developing the MicroRx® platform and discovering new Live Biotherapeutics. After completing her BSc and MSc in Biology at Wageningen University in the Netherlands, she moved to Aberdeen for her PhD, studying on the effects of dietary components on the gut immune system. Imke then carried out 8 years of post-doctoral work as a Research Fellow in the Gut Immunology Group at the Rowett Institute of Nutrition and Health (RINH) in Aberdeen. This work primarily focused on interactions between the gut microbiota and the host immune system in different model organisms.

 

An insightful Q&A session follows the presentation involving analysts from Chardan, N+1 Singer, Bryan, Garnier & Co., Cantor Fitzgerald, Jeffries, Jones Trading and

Ladenburg Thalmann & Co. No material new information is provided in the webinar.

 

 

 

 

About 4D

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform, MicroRx(R), that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

 

4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical studies in progress, namely a Phase II clinical study of BLAUTIX(R) in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

 

 

Contact Information:

4D

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130

Investor Relations ir@4dpharmaplc.com

 

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Aubrey Powell / Justin McKeegan / Iqra Amin (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Image Box Communications

Neil Hunter / Michelle Boxall +44 (0)20 8943 4685

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAEASNFESKEEFA

Quick facts: 4D pharma plc

Price: 93.2

Market: LSE
Market Cap: £122.46 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read